Liraglutide facilitates myocardial restoration to inhibit myocardial infarction by the upregulation of SIRT1 and Parkin, activation of mitophagy, reduction in cellular oxidative stress, optimum redox state, and mitochondrial homeostasis [101]. This evidence concerns the gene PRKN and myocardial infarction.